Can AI Cure Every Disease in 10 Years? | Conversations in Action

Biotech investor Peter Kolchinsky argues that while AI significantly accelerates drug discovery, it cannot bypass the essential, time-consuming reality of human clinical trials. Drug development remains a slow, iterative process requiring rigorous verification to ensure safety and efficacy, rather than a purely computational problem. The industry relies on a capitalist framework to incentivize the creation of life-saving treatments, such as HIV antivirals and epinephrine delivery systems, which ultimately reduce long-term healthcare costs by preventing hospitalizations. Beyond current therapeutic breakthroughs, the future of medicine lies in preventative interventions, including the potential for over-the-counter GLP-1 patches to manage metabolic health. True medical progress demands a balance between technological innovation and the practical, ethical, and economic constraints of bringing new medicines to patients, emphasizing that steady, incremental advancements remain the most reliable path to curing complex conditions like celiac disease and cancer.